Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Michels

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
International Journal of Retina and Vitreous|November 17, 2016
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot studyMagdalena A Wirth, Matthias D Becker, Nicole Graf, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 16, 2006
Three-dimensional imaging of pigment epithelial detachment in age-related macular degeneration using optical coherence tomography, retinal thickness analysis and topographic angiographyChristian Ahlers, Stephan Michels, Arne Beckendorf, et al.
Acta Ophthalmologica Scandinavica|April 6, 2007
Retinal pigment epithelium tears following intravitreal ranibizumab therapyChristopher Kiss, Stephan Michels, Franz Prager, et al.
The British Journal of Ophthalmology|April 17, 2015
Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degenerationKyriaki Mazaraki, Heidi Fassnacht-Riederle, Robert Blum, et al.
Retina (Philadelphia, Pa.)|May 9, 2008
Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapyFranz Prager, Stephan Michels, Christian Simader, et al.
The British Journal of Ophthalmology|October 20, 2006
Effect of systemic bevacizumab therapy on retinal pigment epithelial detachmentMatthias Bolz, Stephan Michels, Wolfgang Geitzenauer, et al.
Current Eye Research|July 16, 2005
Mechanism of photodynamic occlusion using liposomal Zn(II)-phtalocyanineUrsula Schmidt-Erfurth, Stephan Michels, Lars Indorf, et al.
Journal of Ophthalmology|March 21, 2017
Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptJuliana Wons, Magdalena A Wirth, Nicole Graf, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
COMPARISON OF RESOLUTION OF VITREOMACULAR TRACTION AFTER OCRIPLASMIN TREATMENT OR VITRECTOMYPaula Scholz, Vasilena Sitnilska, Jelka Hess, et al.
Ophthalmic Research|September 29, 2015
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionMaximilian Pfau, Heidi Fassnacht-Riederle, Matthias D Becker, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
International Journal of Retina and Vitreous|November 17, 2016
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot studyMagdalena A Wirth, Matthias D Becker, Nicole Graf, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 16, 2006
Three-dimensional imaging of pigment epithelial detachment in age-related macular degeneration using optical coherence tomography, retinal thickness analysis and topographic angiographyChristian Ahlers, Stephan Michels, Arne Beckendorf, et al.
Acta Ophthalmologica Scandinavica|April 6, 2007
Retinal pigment epithelium tears following intravitreal ranibizumab therapyChristopher Kiss, Stephan Michels, Franz Prager, et al.
The British Journal of Ophthalmology|April 17, 2015
Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degenerationKyriaki Mazaraki, Heidi Fassnacht-Riederle, Robert Blum, et al.
Retina (Philadelphia, Pa.)|May 9, 2008
Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapyFranz Prager, Stephan Michels, Christian Simader, et al.
The British Journal of Ophthalmology|October 20, 2006
Effect of systemic bevacizumab therapy on retinal pigment epithelial detachmentMatthias Bolz, Stephan Michels, Wolfgang Geitzenauer, et al.
Current Eye Research|July 16, 2005
Mechanism of photodynamic occlusion using liposomal Zn(II)-phtalocyanineUrsula Schmidt-Erfurth, Stephan Michels, Lars Indorf, et al.
Journal of Ophthalmology|March 21, 2017
Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptJuliana Wons, Magdalena A Wirth, Nicole Graf, et al.
Retina (Philadelphia, Pa.)|November 15, 2017
COMPARISON OF RESOLUTION OF VITREOMACULAR TRACTION AFTER OCRIPLASMIN TREATMENT OR VITRECTOMYPaula Scholz, Vasilena Sitnilska, Jelka Hess, et al.
Ophthalmic Research|September 29, 2015
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusionMaximilian Pfau, Heidi Fassnacht-Riederle, Matthias D Becker, et al.
Pageof 8